Convergent Therapeutics Announces $90 Million Series A Financing To Advance The Clinical Development Of Radiopharmaceuticals For The Treatment Of Prostate Cancer And Other Solid Tumors
Amount Raised
$90 Million
Round Type
Series A
CambridgeBiotechnologyHealth CareTherapeuticsInvestors
Description
Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the completion of a $90 million Series A financing, led by OrbiMed and RA Capital Management with participation from Invus. The financing will support the development of a pipeline of novel radioantibodies, including its lead program with CONV01-α, for the treatment of advanced prostate cancer.
Quick answer
Convergent Therapeutics raised $90 Million in a Series A round, dated May 3, 2023. Investors: Invus, RA Capital Management and Orbi Med. Convergent Therapeutics is based in Cambridge, Massachusetts, United States.
- How much did Convergent Therapeutics raise?
- Convergent Therapeutics raised $90 Million in a Series A round on May 3, 2023.
- Who invested in Convergent Therapeutics?
- Invus, RA Capital Management and Orbi Med are named as investors in this round.
- What does Convergent Therapeutics do?
- Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer.
- Where is Convergent Therapeutics based and how big is it?
- Convergent Therapeutics is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at Convergent Therapeutics?
- Fundz holds 1 contact at Convergent Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Convergent Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Metagen Therapeutics raised an undisclosed amount (Series A) on June 15, 2023.
- Zucara Therapeutics raised an undisclosed amount (Funding Round) on June 15, 2023.
- Eccogene raised $25M (Series B) on June 12, 2023.
- Kate Therapeutics raised $51M (Series A) on June 8, 2023.
- Acepodia raised $100M (Series D) on June 6, 2023.
- Alkeus Pharmaceuticals raised $150M (Series B) on June 5, 2023.
Who to call at Convergent Therapeutics, and when
A new round usually means Convergent Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Convergent Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Convergent Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Convergent Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Convergent Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansConvergent Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.